Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51.
For the 2024 fourth quarter, Pediatrix reported the following results:
- Net revenue of $502 million;
- Net income of $30 million; and
- Adjusted EBITDA of $69 million.
"Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "I am honored and excited to reassume the role of Chief Executive Officer, and I am committed to furthering the Company's strategic focus on supporting clinical excellence, strengthening our hospital and health system relationships, and optimizing our operating efficiency. We believe this focus, supported by our financial strength, will benefit all of our stakeholders."
Operating Results– Three Months Ended December 31, 2024
Pediatrix's net revenue for the three months ended December 31, 2024 was $502.4 million, compared to $496.4 million for the prior-year period. This increase reflected growth in same-unit revenue of 8.7 percent, partially offset by the impact of non-same unit activity, primarily practice dispositions.
Same-unit revenue from net reimbursement-related factors increased by 5.9 percent for the 2024 fourth quarter as compared to the prior-year period. This increase primarily reflects improved payor mix and modest improvements in hospital contract administrative fees. The percentage of services reimbursed by commercial and other non-government payors increased by approximately 200 basis points compared to the prior year period.
Same-unit revenue attributable to patient volume increased by 2.8 percent for the 2024 fourth quarter as compared to the prior-year period. Shown below are year-over-year percentage changes in certain same-unit volume statistics for the three months and year ended December 31, 2024. (Note: figures in the below table reflect contributions only to net patient service revenue and exclude other contributions to total same-unit revenue, including contract and administrative fees.)
|
|
Three Months Ended
|
|
Year Ended
|
|
|
|
|
|
Hospital-based patient services |
|
2.6% |
|
1.9% |
Office-based patient services |
|
6.4% |
|
4.0% |
|
|
|
|
|
Neonatology services (within hospital-based services): |
|
|
|
|
Neonatal intensive care unit (NICU) days |
|
2.8% |
|
1.3% |
For the 2024 fourth quarter, practice salaries and benefits expense was $349.0 million, compared to $363.6 million for the prior-year period. This comparison primarily reflects the impact of practice disposition activity, partially offset by increases in same-unit clinical compensation costs, including incentive compensation based on practice results.
For the 2024 fourth quarter, general and administrative expenses were $63.6 million, as compared to $53.1 million for the prior-year period. This comparison primarily reflects higher incentive compensation based on financial results.
For 2024 fourth quarter, transformational and restructuring related expenses totaled $23.6 million. These expenses related primarily to practice dispositions, revenue cycle management transition activities and position eliminations.
Adjusted EBITDA, which is defined as earnings before interest, taxes, depreciation and amortization, transformational and restructuring related expenses, adjustments to goodwill impairment and loss on disposal of businesses, was $68.7 million for the 2024 fourth quarter, compared to $50.8 million for the prior-year period.
Depreciation and amortization expense was $6.9 million for the fourth quarter of 2024, compared to $9.1 million for the prior-year period. This comparison was primarily related to a decrease in depreciation expense related to non-same unit activity, primarily practice dispositions.
Interest expense was $9.7 million for the fourth quarter of 2024, compared to $10.1 million for the fourth quarter of 2023.
Pediatrix generated net income of $30.5 million, or $0.36 per diluted share, for the 2024 fourth quarter, based on a weighted average 85.2 million shares outstanding. This compares with a net loss of $124.3 million, or $1.50 per diluted share, for the 2023 fourth quarter, based on a weighted average 82.7 million shares outstanding.
For the fourth quarter of 2024, Pediatrix reported Adjusted EPS of $0.51, compared to $0.32 for the fourth quarter of 2023. For these periods, Adjusted EPS is defined as diluted income per common and common equivalent share excluding non-cash amortization expense, stock-based compensation expense, transformational and restructuring related expenses, loss on disposal of businesses, tax effects and related adjustments to goodwill impairment and discrete tax events.
Operating Results – Year Ended December 31, 2024
For the year ended December 31, 2024, Pediatrix generated revenue of $2.01 billion, compared to $1.99 billion for the prior-year period. Pediatrix generated a net loss of $99.1 million, or $1.19 per share, for the year ended December 31, 2024, based on a weighted average 83.3 million shares outstanding, which compares to a net loss of $60.4 million, or $0.73 per share, based on a weighted average 82.2 million shares outstanding for prior year. Adjusted EBITDA for the year ended December 31, 2024 was $224.0 million, compared to $200.4 million for the prior year. For the year ended December 31, 2024, Pediatrix reported Adjusted EPS of $1.51, compared to $1.26 in the same period of 2023.
Financial Position and Cash Flow – Continuing Operations
Pediatrix had cash and cash equivalents of $229.9 million at December 31, 2024, compared to $73.3 million at December 31, 2023, and net accounts receivable at December 31, 2024 were $260.0 million.
For the fourth quarter of 2024, Pediatrix generated cash from continuing operations of $134.8 million, compared to $73.0 million during the fourth quarter of 2023. During the fourth quarter of 2024, the Company used $3.4 million to fund capital expenditures.
At December 31, 2024, Pediatrix had total debt outstanding of $616 million, consisting of its $400 million in 5.375% Senior Notes due 2030 and $216 million in borrowings under its Term A Loan. At December 31, 2024, the Company had no outstanding borrowings under its $450 million revolving line of credit.
Portfolio Management Update
As previously disclosed, during the second quarter of 2024, Pediatrix formalized its practice portfolio management plans, resulting in a decision to exit almost all of its affiliated office-based practices and its primary and urgent care service line.
The Company completed these plans on or prior to December 31, 2024. In aggregate, the office-based practices that the Company exited and the primary and urgent care clinics that have been divested contributed net revenue of approximately $200 million in 2023. As previously disclosed, Pediatrix expects that the annualized favorable impact to Adjusted EBITDA resulting from its portfolio management plans to be approximately $30 million, based on 2023 financial information. A portion of this expected favorable impact was realized during 2024.
Preliminary 2025 Outlook
On a preliminary basis, Pediatrix anticipates that its 2025 Adjusted EBITDA, as defined above, will be in a range of $215 million to $235 million.
Non-GAAP Measures
A reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable GAAP measures for the three months and year ended December 31, 2024 and 2023 is provided in the financial tables of this press release.
Earnings Conference Call
Pediatrix will host an investor conference call to discuss the quarterly results at 9 a.m., ET today. The conference call Webcast may be accessed from the Company's Website, www.pediatrix.com. A replay of the conference call will also be available at www.pediatrix.com.
ABOUT PEDIATRIX MEDICAL GROUP
Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group's high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,400 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.
Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company's objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made by the Company's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company's most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled "Risk Factors", as well the Company's current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the Company's practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the impact of the Company's termination of its then third-party revenue cycle management provider and transition to a hybrid revenue cycle management model with one or more new third-party service providers, including any transition costs associated therewith; the impact of surprise billing legislation; the effects of economic conditions on the Company's business; the effects of the Affordable Care Act and potential healthcare reform; the Company's relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company's ability to comply with the terms of its debt financing arrangements; the impact of management transitions; the timing and contribution of future acquisitions or organic growth initiatives; the effects of share repurchases; and the effects of the Company's transformation initiatives, including its reorientation on, and growth strategy for, its hospital based and maternal fetal businesses.
Pediatrix Medical Group, Inc. Consolidated Statements of Income and Comprehensive Income (in thousands, except per share data) (Unaudited) |
||||||||||||||||
|
|
Three Months Ended
|
|
|
Twelve Months Ended
|
|
||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Net revenue |
|
$ |
502,364 |
|
|
$ |
496,443 |
|
|
$ |
2,012,919 |
|
|
$ |
1,994,640 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Practice salaries and benefits |
|
|
348,993 |
|
|
|
363,604 |
|
|
|
1,440,827 |
|
|
|
1,448,275 |
|
Practice supplies and other operating expenses |
|
|
24,845 |
|
|
|
31,672 |
|
|
|
117,748 |
|
|
|
124,800 |
|
General and administrative expenses |
|
|
63,553 |
|
|
|
53,064 |
|
|
|
238,437 |
|
|
|
227,542 |
|
Depreciation and amortization |
|
|
6,873 |
|
|
|
9,062 |
|
|
|
32,226 |
|
|
|
36,171 |
|
Transformational and restructuring related expenses |
|
|
23,641 |
|
|
|
2,219 |
|
|
|
64,260 |
|
|
|
2,219 |
|
Goodwill impairment |
|
|
(3,599 |
) |
|
|
148,312 |
|
|
|
150,644 |
|
|
|
148,312 |
|
Long-lived asset impairments |
|
|
— |
|
|
|
— |
|
|
|
27,791 |
|
|
|
— |
|
(Gain) loss on disposal of businesses |
|
|
(1,233 |
) |
|
|
— |
|
|
|
9,699 |
|
|
|
— |
|
Total operating expenses |
|
|
463,073 |
|
|
|
607,933 |
|
|
|
2,081,632 |
|
|
|
1,987,319 |
|
Income (loss) from operations |
|
|
39,291 |
|
|
|
(111,490 |
) |
|
|
(68,713 |
) |
|
|
7,321 |
|
Investment and other income |
|
|
2,830 |
|
|
|
2,242 |
|
|
|
5,771 |
|
|
|
4,338 |
|
Interest expense |
|
|
(9,710 |
) |
|
|
(10,081 |
) |
|
|
(40,743 |
) |
|
|
(42,075 |
) |
Impairment of strategic investment |
|
|
— |
|
|
|
(20,000 |
) |
|
|
— |
|
|
|
(20,000 |
) |
Equity in earnings of unconsolidated affiliate |
|
|
917 |
|
|
|
479 |
|
|
|
2,344 |
|
|
|
2,057 |
|
Total non-operating expenses |
|
|
(5,963 |
) |
|
|
(27,360 |
) |
|
|
(32,628 |
) |
|
|
(55,680 |
) |
Income (loss) before income taxes |
|
|
33,328 |
|
|
|
(138,850 |
) |
|
|
(101,341 |
) |
|
|
(48,359 |
) |
Income tax (provision) benefit |
|
|
(2,848 |
) |
|
|
14,563 |
|
|
|
2,272 |
|
|
|
(12,049 |
) |
Net income (loss) |
|
$ |
30,480 |
|
|
$ |
(124,287 |
) |
|
$ |
(99,069 |
) |
|
$ |
(60,408 |
) |
Other comprehensive income (loss), net of tax |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Unrealized holding (loss) gain on investments, net of
|
|
|
(862 |
) |
|
|
1,303 |
|
|
|
1,143 |
|
|
|
1,521 |
|
Total comprehensive income (loss) |
|
$ |
29,618 |
|
|
$ |
(122,984 |
) |
|
$ |
(97,926 |
) |
|
$ |
(58,887 |
) |
Per common and common equivalent share data (diluted): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income (loss): |
|
$ |
0.36 |
|
|
$ |
(1.50 |
) |
|
$ |
(1.19 |
) |
|
$ |
(0.73 |
) |
Weighted average common shares |
|
|
85,160 |
|
|
|
82,660 |
|
|
|
83,330 |
|
|
|
82,201 |
|
Pediatrix Medical Group, Inc. Reconciliation of Net Income (Loss) to Adjusted EBITDA (in thousands) (Unaudited) |
||||||||||||||||
|
|
Three Months Ended
|
|
|
Twelve Months Ended
|
|
||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Net income (loss) |
|
$ |
30,480 |
|
|
$ |
(124,287 |
) |
|
$ |
(99,069 |
) |
|
$ |
(60,408 |
) |
Interest expense |
|
|
9,710 |
|
|
|
10,081 |
|
|
|
40,743 |
|
|
|
42,075 |
|
Income tax provision (benefit) |
|
|
2,848 |
|
|
|
(14,563 |
) |
|
|
(2,272 |
) |
|
|
12,049 |
|
Depreciation and amortization expense |
|
|
6,873 |
|
|
|
9,062 |
|
|
|
32,226 |
|
|
|
36,171 |
|
Transformational and restructuring related expenses |
|
|
23,641 |
|
|
|
2,219 |
|
|
|
64,260 |
|
|
|
2,219 |
|
Impairment losses |
|
|
(3,599 |
) |
|
|
168,312 |
|
|
|
178,435 |
|
|
|
168,312 |
|
(Gain) loss on disposal of businesses |
|
|
(1,233 |
) |
|
|
— |
|
|
|
9,699 |
|
|
|
— |
|
Adjusted EBITDA |
|
$ |
68,720 |
|
|
$ |
50,824 |
|
|
$ |
224,022 |
|
|
$ |
200,418 |
|
Pediatrix Medical Group, Inc. Reconciliation of Diluted Net Income (Loss) per Share to Adjusted Income per Diluted Share ("Adjusted EPS") (in thousands, except per share data) (Unaudited) |
||||||||||||||||
|
|
Three Months Ended
|
|
|||||||||||||
|
|
2024 |
|
|
2023 |
|
||||||||||
Weighted average diluted shares outstanding |
|
|
85,160 |
|
|
|
|
|
|
82,660 |
|
|
|
|
||
Net income (loss) and diluted net income (loss) per share |
|
$ |
30,480 |
|
|
$ |
0.36 |
|
|
$ |
(124,287 |
) |
|
$ |
(1.50 |
) |
Adjustments (1): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Amortization (net of tax of $531 and $502) |
|
|
1,594 |
|
|
|
0.02 |
|
|
|
1,510 |
|
|
|
0.02 |
|
Stock-based compensation (net of tax of $601 and $756) |
|
|
1,804 |
|
|
|
0.02 |
|
|
|
2,268 |
|
|
|
0.03 |
|
Transformational and restructuring expenses (net of tax of $5,910 and $555) |
|
|
17,731 |
|
|
|
0.21 |
|
|
|
1,664 |
|
|
|
0.02 |
|
Impairment losses (net of tax of $ - and $42,078) |
|
|
(6,659 |
) |
|
|
(0.08 |
) |
|
|
126,234 |
|
|
|
1.53 |
|
Gain on disposal of businesses (net of tax of $308) |
|
|
(925 |
) |
|
|
(0.01 |
) |
|
|
— |
|
|
|
— |
|
Net impact from discrete tax events |
|
|
(544 |
) |
|
|
(0.01 |
) |
|
|
18,841 |
|
|
|
0.22 |
|
Adjusted income and diluted EPS |
|
$ |
43,481 |
|
|
$ |
0.51 |
|
|
$ |
26,230 |
|
|
$ |
0.32 |
|
(1) |
A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended December 31, 2024 and 2023, other than impairment losses for the three months ended December 31, 2024. The impairment losses reflect tax effects and related adjustments to goodwill impairment recognized in the second quarter of 2024. |
|
|
Twelve Months Ended
|
|
|||||||||||||
|
|
2024 |
|
|
2023 |
|
||||||||||
Weighted average diluted shares outstanding |
|
|
83,330 |
|
|
|
|
|
|
82,201 |
|
|
|
|
||
Net (loss) income and diluted net (loss) income per share |
|
$ |
(99,069 |
) |
|
$ |
(1.19 |
) |
|
$ |
(60,408 |
) |
|
$ |
(0.73 |
) |
Adjustments (1): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Amortization (net of tax of $2,373 and $2,010) |
|
|
7,120 |
|
|
|
0.09 |
|
|
|
6,032 |
|
|
|
0.07 |
|
Stock-based compensation (net of tax of $2,473 and $3,081) |
|
|
7,420 |
|
|
|
0.09 |
|
|
|
9,242 |
|
|
|
0.11 |
|
Transformational and restructuring related expenses (net of tax of $16,065 and $555) |
|
|
48,195 |
|
|
|
0.58 |
|
|
|
1,664 |
|
|
|
0.02 |
|
Impairment losses (net of tax of $31,633 and $42,078) |
|
|
146,802 |
|
|
|
1.76 |
|
|
|
126,234 |
|
|
|
1.54 |
|
Loss on disposal of businesses (net of tax of $2,425) |
|
|
7,274 |
|
|
|
0.09 |
|
|
|
— |
|
|
|
— |
|
Net impact from discrete tax events |
|
|
7,912 |
|
|
|
0.09 |
|
|
|
20,825 |
|
|
|
0.25 |
|
Adjusted income and diluted EPS |
|
$ |
125,654 |
|
|
$ |
1.51 |
|
|
$ |
103,589 |
|
|
$ |
1.26 |
|
(1) |
A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the twelve months ended December 31, 2024 and 2023, other than for impairment losses for the year ended December 31, 2024, due to a portion of the expenses being non-deductible. |
Pediatrix Medical Group, Inc. Balance Sheet Highlights (in thousands) (Unaudited) |
||||||||
|
|
As of
|
|
|
As of
|
|
||
Assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
229,940 |
|
|
$ |
73,258 |
|
Investments |
|
|
118,566 |
|
|
|
104,485 |
|
Accounts receivable, net |
|
|
259,990 |
|
|
|
272,313 |
|
Other current assets |
|
|
31,111 |
|
|
|
33,398 |
|
Intangible assets, net |
|
|
11,595 |
|
|
|
21,240 |
|
Operating and finance lease right-of-use assets |
|
|
39,267 |
|
|
|
70,294 |
|
Goodwill, other assets, property and equipment |
|
|
1,462,231 |
|
|
|
1,644,822 |
|
Total assets |
|
$ |
2,152,700 |
|
|
$ |
2,219,810 |
|
Liabilities and shareholders' equity: |
|
|
|
|
|
|
||
Accounts payable and accrued expenses |
|
$ |
398,690 |
|
|
$ |
350,798 |
|
Total debt, including finance leases, net |
|
|
617,664 |
|
|
|
633,334 |
|
Operating lease liabilities |
|
|
44,649 |
|
|
|
68,314 |
|
Other liabilities |
|
|
326,759 |
|
|
|
318,303 |
|
Total liabilities |
|
|
1,387,762 |
|
|
|
1,370,749 |
|
Total shareholders' equity |
|
|
764,938 |
|
|
|
849,061 |
|
Total liabilities and shareholders' equity |
|
$ |
2,152,700 |
|
|
$ |
2,219,810 |
|
Pediatrix Medical Group, Inc. Reconciliation of Net Income to Forward-Looking Adjusted EBITDA (in thousands) (Unaudited) |
||||||||
|
|
Year Ended
|
|
|||||
|
|
|
|
|
|
|
||
Net Income |
|
$ |
98,310 |
|
|
$ |
112,910 |
|
Interest expense |
|
|
37,860 |
|
|
|
37,860 |
|
Income tax expense |
|
|
36,400 |
|
|
|
41,800 |
|
Depreciation and amortization expense |
|
|
27,530 |
|
|
|
27,530 |
|
Transformational and restructuring related expenses |
|
|
14,900 |
|
|
|
14,900 |
|
Adjusted EBITDA |
|
$ |
215,000 |
|
|
$ |
235,000 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220684360/en/
Charles Lynch
Senior Vice President, Finance and Strategy
954-384-0175, x 5692
[email protected]